← Leaderboards
Bob D. Brown
Dicerna Pharmaceuticals, Inc.
$4,682,738
Attributed
$7,182,738
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.5M · FY2015–21$2M$1.5M$1M$500K$0
'15
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$7,182,738 · 3
By mechanism
U44$5,000,000 · 1
R44$1,998,609 · 1
R43$184,129 · 1
Top collaborators
- Henryk Dudek4 shared
Most similar at Dicerna Pharmaceuticals, Inc.
Same institution · by research overlap
- Henryk Dudek$2,500,000
Others in their field
Top investigators on “Pharmaceutical Preparations”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$266,816,120
- Leonard Freedman · Leidos Biomedical Research, Inc.$240,520,687
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$196,976,947
- Lawrence Corey · Fred Hutchinson Cancer Center$196,976,947
Research focus
Pharmaceutical PreparationsLiverToxicologyMessenger RnaRna InterferenceSuccessSurveysCyclic GmpMeetingsDoseMeasurementPre-ClinicalSmall Business Innovation Research GrantSmall Interfering RnaAnimalsClinical TrialsSafetyPhase I Clinical TrialsNonhuman PrimatePreparationIn VitroGenesClinical DevelopmentResponse
Grant awards (7)
Development of an ALDH2-Targeting RNAi Therapeutic for Alcohol Use Disorders$1,500,000
U44 · FY2021 · AA
Development of an ALDH2-Targeting RNAi Therapeutic for Alcohol Use Disorders$1,500,000
U44 · FY2020 · AA
Development of an ALDH2-Targeting RNAi Therapeutic for Alcohol Use Disorders$1,000,000
U44 · FY2019 · AA
Development of an ALDH2-Targeting RNAi Therapeutic for Alcohol Use Disorders$1,000,000
U44 · FY2018 · AA
Optimization of a clinical stage nanoparticle drug delivery platform$998,609
R44 · FY2017 · CA · contact PI
Optimization of a clinical stage nanoparticle drug delivery platform$1,000,000
R44 · FY2016 · CA · contact PI
Optimization of a clinical stage nanoparticle drug delivery platform$184,129
R43 · FY2015 · CA · contact PI